Join BOPA
Back to news articles

BOPA Abstract deadline EXTENDED To midnight Sunday 14th July 2024

By BOPA research subcommittee on 2nd July 2024

The deadline for abstracts for this year’s BOPA 2024 conference in Birmingham has been extended. Delegates are invited to present results of their clinical and technical work as a poster with some selected as an oral presentation.  The author/s should submit via the BOPA website by midnight on Sunday 14th July 2024.

Abstracts will be reviewed and marked by the BOPA Audit and Research Sub-Committee, and chosen authors will be invited to display their poster for the duration of the conference, with the posters achieving high scores selected for oral presentation.

Selected abstracts will be published in a supplement to the Journal of Oncology Pharmacy Practice (JOPP), providing authors with a citation in a peer reviewed journal.

Further information can be found here

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article